טוען...
Profile of tivantinib and its potential in the treatment of hepatocellular carcinoma: the evidence to date
Hepatocellular carcinoma (HCC) is the fastest rising cause of cancer-related death in the United States and carries a very poor prognosis, with a median survival time of <50% at 1 year for advanced disease. To date, sorafenib is the only therapy approved by the Food and Drug Administration for th...
שמור ב:
| הוצא לאור ב: | J Hepatocell Carcinoma |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Dove Medical Press
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5118026/ https://ncbi.nlm.nih.gov/pubmed/27896243 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JHC.S106072 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|